Is Xeloda affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: DPYD

Used for: Colorectal, breast, and gastric cancers (oral chemotherapy)

Xeloda (capecitabine) is one of the few medications where a pharmacogenetic test is considered standard of care before the first dose, not optional. Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) inside your body. 5-FU is then broken down by the DPYD-encoded enzyme dihydropyrimidine dehydrogenase. A small but clinically critical fraction of people carry reduced-function DPYD variants, meaning they can't clear 5-FU effectively. For those patients, a standard capecitabine dose can cause severe, life-threatening toxicity: neutropenia, severe mucositis, diarrhea, and in the worst cases, death. Multiple regulatory agencies (including the EMA in Europe) now require or strongly recommend DPYD testing before starting capecitabine or IV 5-FU.

What's in Xeloda

capecitabine affected by DPYD

Affected by DPYD · CPIC, FDA · Strong evidence

Capecitabine undergoes a three-step conversion in the body, ending with 5-FU at the tumor site. The DPYD enzyme is responsible for catabolizing 5-FU, and reduced DPYD activity means 5-FU accumulates far above expected levels. About 3 to 5 percent of people of European descent carry a heterozygous reduced-function DPYD variant; true complete deficiency is rare (roughly 0.1 percent) but catastrophic when missed. CPIC recommends a 50 percent dose reduction for intermediate DPYD activity and avoidance of the drug for complete deficiency.

Read the full capecitabine genetics guide →

Capecitabine phenotype recommendations

Published guidance from CPIC and FDA on how capecitabine should be dosed or substituted based on your DPYD phenotype.

Phenotype	What it means	Recommendation	Evidence
Normal Metabolizer DPYD	Your body processes capecitabine normally. You have a typical risk of side effects, and the standard dose is expected to be appropriate.	CPIC Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration FDA Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer DPYD	Your body processes capecitabine more slowly than normal, which increases the risk of severe side effects. Your doctor will likely start you on a lower dose and adjust based on how you respond.	CPIC + CPIC Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose. FDA Insufficient data to recommend a specific dosage. Withhold or discontinue in the presence of early-onset or unusually severe toxicity. Refer to FDA labeling for specific recommendations.	Strong
Poor Metabolizer DPYD	Your body has very limited ability to process capecitabine, putting you at high risk for severe or life-threatening side effects. Your doctor may avoid this drug or use a much lower dose with close monitoring.	CPIC + CPIC Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.l Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. FDA Avoid capecitabine. No dosage has proven safe in poor metabolizers. Consider an alternative treatment.	Strong
Indeterminate DPYD	The impact of your genotype on response to this drug is unknown	CPIC + FDA Initiate therapy with recommended starting dose.	—
Not available DPYD	The impact of your genotype on response to this drug is unknown	CPIC + FDA Initiate therapy with recommended starting dose.	—

Sources: CPIC, FDA

The gene behind the guidance

DPYD Dihydropyrimidine Dehydrogenase

DPYD breaks down fluoropyrimidine chemotherapy drugs (5-FU, capecitabine). A small percentage of people carry reduced-function variants that cause the drug to accumulate to toxic levels. This is one of the few pharmacogenetic tests that is mandatory in many oncology guidelines before starting treatment.

Partial DPYD deficiency calls for a 25 to 50 percent dose reduction. Complete deficiency is a contraindication: standard-dose fluoropyrimidine can be fatal.

See all drugs affected by DPYD →

Browse the full drug-class: Chemotherapy agents.

What this means for you

If you or a family member has been prescribed Xeloda (or IV 5-FU), ask whether DPYD testing has been done. Many oncology centers now do this as a matter of course, but not all. The test is inexpensive, results come back in a few days, and the downside of not testing is meaningful: DPYD-related fluoropyrimidine toxicity accounts for a real share of chemotherapy hospitalizations and deaths that would have been prevented by a single genetic test up front.

FAQ

Why isn't DPYD testing universal in the US yet?

It's moving that direction. The European Medicines Agency requires DPYD testing before starting fluoropyrimidines, and guidelines from NCCN, ASCO, and CPIC all recommend it in the US. Uptake has been slower than in Europe, partly because of insurance coverage variability and partly because of inertia in how chemotherapy orders get written, but most major cancer centers in the US now test routinely.

Can side effects from Xeloda be explained by something other than DPYD?

Yes. Many people have significant side effects on capecitabine even with fully functional DPYD, and those side effects are more about the drug's inherent toxicity than about genetics. The DPYD story is specifically about severe, disproportionate toxicity that develops quickly in the first cycles. If someone has gradual fatigue and moderate mucositis, that's usually just capecitabine. If someone has grade 4 neutropenia and collapse in the first week, that's the pattern that DPYD testing would have flagged.

If I have a DPYD variant, does that mean no chemotherapy?

It means no standard-dose fluoropyrimidine. Intermediate DPYD function means a dose reduction (often 25 to 50 percent) with continued monitoring, and most patients can still tolerate and benefit from capecitabine at that reduced dose. Complete DPYD deficiency is a contraindication to fluoropyrimidines, but many other chemotherapy classes are available and are not affected by DPYD.

Find out how your genetics affect Xeloda

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.